Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancer
Shots:
- Tessa to conduct a P-Ib/II trial assessing Tessa’s human papillomavirus-specific T cell (HPVST) therapy or TT12 with Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer
- The P-Ib/II trial will be initiated in the US- Singapore- South Korea. Additionally- Tessa’s TT12 and an anti PD-1 therapy is being evaluated in P-I for patients with relapsed HPV-associated cancers- resulted in well-tolerated and minimal toxicity results in the US
- Tessa’s TT12 is an autologous cell therapy based on HPVSTs targeting HPV 16/18 antigens and genetically modified with a decoy TGF-β receptor. Keytruda (pembrolizumab) is an anti-PD-1 therapy involves blocking of the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2
Ref: Tessa Therapeutics | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com